Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate ANK-101 in Combination with Libtayo® (cemiplimab) in Patients with Cutaneous Squamous Cell Carcinoma

by Anand Patadiya | Sep 20, 2024

ANK-101 is a novel first-in-class anchored IL-12 immunotherapy designed for limited anchored delivery to increase immune cell infiltration into tumors and may further increase responses to immune checkpoint inhibitors CAMBRIDGE, MA – November 13, 2023 (BUSINESSWIRE) –...

Ankyra Therapeutics Announces Pre-Clinical Research Published in December JCI Insight Demonstrating Potent Anti-Tumor Activity of Anchored IL-12 in Multiple Murine Cancer Models

by Anand Patadiya | Sep 20, 2024

Pre-clinical studies of ANK-101, an anchored IL-12 therapy, demonstrate the potential of anchored immune medicines to enhance the efficacy and safety profile of cancer immunotherapies CAMBRIDGE, MA – December 12, 2023 (BUSINESSWIRE) – Ankyra Therapeutics, an emerging...

Ankyra Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Dose Escalation Cohort Evaluating ANK-101, an Anchored Immune Medicine, for Solid Tumors

by Anand Patadiya | Sep 20, 2024

Safety and tolerability to be determined at up to 10 study sites in the United States and Canada CAMBRIDGE, MA – March 5, 2024 – Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced the first...

Ankyra Therapeutics and Jenga Biosciences Announce Exclusive License Agreement for JEN‐101

by Anand Patadiya | Sep 20, 2024

March 26, 2024 (Cambridge, MA) – Ankyra Therapeutics and Jenga Biosciences are pleased to announce today an exclusive license agreement to develop and commercialize JEN-101 (formerly known as cANK-101). JEN-101 is a first-in-class, pre-clinical immuno-oncology agent...

Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment

by Anand Patadiya | Sep 20, 2024

Ankyra Therapeutics will provide an update on the status of the ANK-101 Phase 1 ANCHOR clinical trial at ASCO 2024 and has received approval by FDA and Health Canada to amend the Phase I study to include patients with solid tumors in visceral organs June 1, 2024...